Trial Profile
Prospective, multi-centre, randomized, open-label, two arm, parallel group, active control, comparative clinical study to evaluate efficacy and safety of R-TPR-026/ Aranesp when given subcutaneously in patients for correction of anaemia due to Chronic Kidney Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Reliance Life Sciences
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2013 New trial record